Advanced search
Publication Cover
Biomarkers Volume 12, 2007 - Issue 3
Submit an article Journal homepage
610
Views
17
CrossRef citations to date
0
Altmetric
Research Article

Development and validation of a phosphorylated SMAD ex vivo stimulation assay

D. L. Farrington Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, USA
,
J. M. Yingling Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, USA
,
J. A. Fill Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, USA
,
L. Yan Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, USA
,
Y-W. Qian Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, USA
,
J. Shou Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, USA
,
X. Wang Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, USA
,
M. E. Ehsani Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, USA
,
A. L. Cleverly Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, USA
,
T. M. Daly Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, USA
,
M. Lahn Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, USA
,
R. J. Konrad Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, USA
&
C. A. Ray Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, USA
 show all
Pages 313-330 | Received 13 Aug 2006, Published online: 08 Oct 2008

References

  • Bible KC, Lensing JL, Nelson SA, Lee YK, Reid JM, Ames MM, Isham CR, Piens J, Rubin SL, Rubin J, et al. Phase 1 trial of flavopiridol combined with cisplatin or carboplatin in patients with advanced malignancies with the assessment of pharmacokinetic and pharmacodynamic end points. Clinical Cancer Research 2005; 11: 5935–5941
  • Dudley RA, Edwards P, Ekins RP, Finney DJ, McKenzie IG, Raab GM, Rodbard D, Rodgers RP. Guidelines for immunoassay data processing. Clinical Chemistry 1985; 31: 1264–1271
  • Feng XH, Lin X, Derynck R. Smad2, Smad3 and Smad4 cooperate with Sp1 to induce p15(Ink4B) transcription in response to TGF-b. EMBO Journal 2000; 19: 5178–5193
  • Goldsby RA, Kindt TJ, Osborne BA. Kuby Immunology. W.H. Freeman and Company, New York 2000
  • Lagna G, Hata A, Hemmati-Brivanlou A, Massague J. Partnership between DPC4 and SMAD protein in TGF-b signaling pathways. Nature 1996; 383: 832–836
  • Lawrence LW. The phagocytic leukocytes – morphology, kinetics, and function. Clinical Hematology: Principles, Procedures, Correlations, CA Lotspeich-Steininger, EA Stiene-Martin, JA Koepke. J.B. Lippincott Publishers, Philadelphia 1992; 292–302
  • Lee JW, Devanarayan V, Barrett YC, Weiner R, Allinson J, Fountain S, Keller S, Weinryb I, Green M, Duan L, et al. Fit-for-purpose method development and validation for successful biomarker measurement. Pharmaceutical Research 2006; 23: 312–328
  • Lorusso PM, Adjei AA, Varterasian M, Gadgeel S, Reid J, Mitchell DY, Hanson L, DeLuca P, Bruzek L, Piens J, et al. Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies. Journal of Clinical Oncology 2005; 23: 5281–5293
  • Massague J. TGFβ signaling: receptors, transducers, and Mad proteins. Cell 1996; 85: 947–950
  • Massague J, Chen YG. Controlling TGF-b signaling. Genes & Development 2000; 14: 627–644
  • Mead AL, Wong TT, Cordeiro MF, Anderson IK, Khaw PT. Evaluation of anti-TGF-b2 antibody as a new postoperative anti-scarring agent in glaucoma surgery. Investigative Ophthalmology & Visual Science 2003; 44: 3394–3401
  • Nakao A, Imamura T, Souchelnytskyi S, Kawabata M, Ishisaki A, Oeda E, Tamaki K, Hanai J, Heldin CH, Miyazono K, et al. TGF-b receptor-mediated signaling through Smad2, Smad3 and Smad4. EMBO Journal 1997; 16: 5353–5362
  • Peralba JM, DeGraffenried L, Friedrichs W, Fulcher L, Grunwald V, Weiss G, Hidalgo M. Pharmacodynamic Evaluation of CCI-779, an Inhibitor of mTOR, in Cancer Patients. Clinical Cancer Research 2003; 9: 2887–2892
  • Qing J, Zhang Y, Derynck R. Structural and functional characterization of the transforming growth factor-b-induced Smad3/c-Jun transcriptional cooperativity. Journal of Biological Chemistry 2000; 275: 38802–38812
  • Schlingensiepen KH, Schlingensiepen R, Steinbrecher A, Hau P, Bogdahn U, Fischer-Blass B, Jachimczak P. Targeted tumour therapy with the TGF-b2 antisense compound AP 12009. Cytokine Growth Factor Review 2006; 17: 129–139
  • Shi Y, Massague J. Mechanisms of TGF-b signaling from cell membrane to the nucleus. Cell 2003; 113: 685–700
  • Stopa M, Anhuf D, Terstegen L, Gatsios P, Gressner AM, Dooley S. Participation of Smad2, Smad3, and Smad4 in transforming growth factor b (TGF-b)-induced activation of Smad7. The TGF-b response element of the promoter requires functional Smad binding element and E-box sequences for transcriptional regulation. Journal of Biological Chemistry 2000; 275: 29308–29317
  • Uhl M, Aulwurm S, Wischhusen J, Weiler M, Ma JY, Almirez R, Mangadu R, Liu YW, Platten M, Herrlinger U and others. 2004. SD-208, a novel transforming growth factor b receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo. Cancer Research 64:7954–7961.
  • Wick W, Naumann U, Weller M. Transforming growth factor-b: a molecular target for the future therapy of glioblastoma. Current Pharmaceutical Design 2006; 12: 341–349
  • Wrana JL, Attisano L, Carcamo J, Zentella A, Doody J, Laiho M, Wang X-F, Massague J. TGFβ signals through a heteromeric protein kinase receptor complex. Cell 1992; 71: 1003–1014
  • Wrana JL, Attisano L, Wieser R, Ventura F, Massague J. Mechanism of activation of the TGF-b Receptor. Nature 1994; 370: 341–347
  • Yingling JM, Blanchard KL, Sawyer JS. Development of TGF-b signaling inhibitors for cancer therapy. Nature Review Drug Discovery 2004; 3: 1011–1022
  • Zhang Y, Feng X-H, Wu R-Y, Derynck R. Receptor-associated Mad homologues synergize as effectors of the TGF-b response. Nature 1996; 383: 168–172

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.